涎腺癌切除及颈淋巴结清扫术后辅助治疗对生存的影响
基于美国国家癌症数据库2004至2013年接受治愈性局部切除及颈淋巴结清扫的4145例涎腺癌患者,中位随访54个月。多因素分析显示术后放疗与总生存改善相关,而辅助化疗与生存改善无关。
要点
- 术后放疗与涎腺癌患者总生存改善相关,诊断后≤9个月HR 0.26,>9个月HR 0.75。
- 倾向性评分匹配队列中,术后放疗组5年总生存67.1%,观察组60.6%(P < .001)。
- 辅助化疗与生存改善无关(HR 1.15;95% CI,0.99-1.34;P = .06)。
核心结论
- 术后放疗而非化疗与需要颈淋巴结清扫的涎腺癌患者生存改善相关,该结果不适用于无需颈淋巴结清扫的低危涎腺癌。
研究设计与样本
- 回顾性人群队列研究,数据来自美国国家癌症数据库,纳入2004年至2013年接受手术的涎腺癌患者,要求颈淋巴结清扫至少切除10枚淋巴结,共4145例符合纳入标准,中位随访54个月。
主要发现
- 多因素分析中,术后放疗与总生存改善相关,诊断后≤9个月HR 0.26(95% CI,0.20-0.34;P < .001),>9个月HR 0.75(95% CI,0.66-0.86;P < .001)。
- 倾向性评分匹配队列中,术后放疗组5年总生存67.1%,观察组60.6%(P < .001)。
- 对诊断后生存至少6个月的患者进行界标分析,观察到相似结果。
- 辅助化疗与生存改善无关(HR 1.15;95% CI,0.99-1.34;P = .06)。
临床怎么用
- 作者结论认为,对于需要颈淋巴结清扫的涎腺癌患者,术后放疗与生存改善相关,而化疗与生存改善无关,该结果不适用于无需颈淋巴结清扫的低危涎腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of postoperative radiotherapy (PORT) and chemotherapy on survival in salivary gland cancer (SGC) treated with curative-intent local resection and neck dissection. STUDY DESIGN: Retrospective population-based cohort study. SETTING: National Cancer Database. SUBJECTS AND METHODS: Patients with SGC who were undergoing surgery were identified from the National Cancer Database between 2004 and 2013. Neck dissection removing a minimum of 10 lymph nodes was required. Because PORT violated the proportional hazards assumption, this variable was treated as a time-dependent covariate. RESULTS: Overall, 4145 cases met inclusion criteria (median follow-up, 54 months). PORT was associated with improved overall survival in multivariable analysis, both ≤9 months from diagnosis (hazard ratio [HR], 0.26; 95% CI, 0.20-0.34; P < .001) and >9 months (HR, 0.75; 95% CI, 0.66-0.86; P < .001). In propensity score-matched cohorts, 5-year overall survival was 67.1% and 60.6% with PORT and observation, respectively ( P < .001). Similar results were observed in landmark analysis of patients surviving at least 6 months following diagnosis. Adjuvant chemotherapy was not associated with improved survival (HR, 1.15; 95% CI, 0.99-1.34; P = .06). CONCLUSION: PORT, but not chemotherapy, is associated with improved survival among patients with SGC for whom neck dissection was deemed necessary. These results are not applicable to low-risk SGCs not requiring neck dissection.
引用
- Aro K, Ho AS, Luu M, et al. Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection. Otolaryngol Head Neck Surg. 2019. PMID: 30721113. doi:10.1177/0194599819827851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。